BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late-stage development. Lead candidate Tavocept, which has FDA fast-track status, may prevent nerve and kidney damage caused by cancer therapies. BioNumerik's Karenitecin candidate is an advanced formulation of an existing cancer drug and is being evaluated for treatment of solid tumors. The firm relies heavily on computer models and simulations to identify promising drug candidates. In addition to its two lead candidates, it has several other potential drugs in pre-clinical research.

Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania. Adolor Corporation is a biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. On May 20, 2008, the United States Food and Drug Administration (FDA) approved the Company’s first product, ENTEREG (alvimopan), for the management of postoperative ileus following bowel resection surgery (POI). ENTEREG is specifically indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Company in collaboration with Glaxo Group Limited (Glaxo), launched ENTEREG in the United States in mid-2008.

Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of product candidates providing abuse deterrent features and benefits utilizing its Aversion Technology. The Company’s Aversion Technology platform has been successfully utilized in developing multiple opioid analgesic products candidates. Its portfolio of product candidates includes opioid analgesics to relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules. Acurox is an orally administered immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient.

Merck Sharp & Dohme is the UK subsidiary of American pharmaceutical manufacturer Merck. The company markets such Merck products as arthritis pain treatment Arcoxia (which is approved in Europe but not the US), high blood pressure medication Cozaar, osteoporosis drug Fosamax, and asthma treatment Singulair. It also operates its parent's largest manufacturing facility outside the US, making about 20 medicines at its Cramlington, Northumberland, plant. Its Hoddesdon headquarters handles sales, marketing, and administrative functions; it also includes an R&D center that runs clinical trials and performs research and development activities specializing in organic and synthetic chemistry.

Aspen Pharmacare Holdings is the holding company of Aspen Pharmacare. The company is Africa's largest generic pharmaceutical manufacturer and a major supplier of branded pharmaceutical and healthcare products to southern African and some other international markets. Its products include pain medication, vitamins, cough and cold medicines, laxatives, medicine for indigestion, and aids to help people quit smoking and lose weight. Aspen Pharmacare also led the way in developing the first anti-retroviral medication in South Africa for AIDS treatment. Aspen Pharmacare Holdings Ltd. company has manufacturing facilities in Africa, India, and Latin America.

Cell Therapeutics, Inc. company was founded in 1991 and is headquartered in Seattle, Washington. Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

MiddleBrook Pharmaceuticals was founded in 1999 and is headquartered in Germantown, Maryland. MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products in the United States. The company develops a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of drugs. Its product portfolio includes MOXATAG tablets for the treatment of pharyngitis and tonsillitis; and KEFLEX capsules for the treatment of skin and skin structure infections and upper respiratory tract infections. MiddleBrook Pharmaceuticals sells its products through specialty pharmaceutical distributors and wholesalers to physicians, hospitals, and pharmacies.

PetMed Express, Inc. was founded in 1996 and is headquartered in Pompano Beach, Florida. PetMed Express, Inc. (PetMed) and its subsidiaries, doing business as 1-800-PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses direct to the consumer. The Company markets its products through national television, online, and direct mail/print advertising campaigns. PetMed offers a selection of products for dogs, cats, and horses. As of March 31, 2009, its product line contains approximately 750 stock keeping units (skus). These products include brands of medication, such as Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx and Rimadyl.

Provectus Pharmaceuticals, Inc. company was founded in 2002 and is based in Knoxville, Tennessee. Provectus Pharmaceuticals, Inc., a development stage company, specializes in oncology and dermatology therapies. The company is conducting Phase II clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for psoriasis and atopic dermatitis. It received orphan drug designation from the FDA for its melanoma indication. In addition to its suite of proprietary drugs, Provectus Pharmaceuticals developed various intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.